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Introduction
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin's lymphoma (NHL) . It accounts for approximately 30% to 40% of cases in adults (1). The anti-CD20 antibody rituximab (Rituxan ® ) is commonly used to treat many types of CD20-positive NHL, including DLBCL (2) , and combination therapy of rituximab with standard cytotoxic chemotherapy regimens; such as R-CHOP (rituximab plus cyclophosphamide, hydroxydoxorubicin, vincristine, and prednisone), is the current standard of care for B-cell NHL (3) (4) (5) . However, approximately 30% of the patients either do not respond to or develop resistance to further treatment, and approximately half of relapsed patients are not eligible for high-dose chemotherapy, following autologous stem cell transplantation (6) . Therefore, the development of effective and well-tolerated therapies for elderly, frail, relapsed, or refractory DLBCL patients represents an unmet clinical need.
Bendamustine, a bifunctional alkylating agent containing a nitrogen mustard moiety chemically linked to a purine analogue, is approved treating multiple hematological tumors, including indolent and rituximab-resistant NHL (7) . In large-scale screenings, such as the National Cancer Institute (NCI) In Vitro Cell Line Screening Project and gene microarrays, bendamustine showed a unique mechanistic profile, which included activation of DNA damage stress responses and apoptosis, inhibition of mitotic checkpoints, and induction of mitotic catastrophe, when compared with most other conventional alkylators such as cyclophosphamide and melphalan (8) . Further, bendamustine exhibited limited cross-resistance to other alkylating agents and showed prolonged effects towards DNA damage (9) . In vitro, CD20-positive DLBCL and primary chronic lymphocytic leukemia (CLL) cell lines showed a synergistic effect toward the combination use of bendamustine with rituximab (10) . Further, the (27) . These findings suggested that YM155 was clinically active against DLBCL, when combined with rituximab.
Given the above, we hypothesized that a triple combination of YM155 with bendamustine and rituximab would show enhanced antitumor activity when compared to the combination of these two agents alone against DLBCL. Here, we examined the antitumor activity of YM155 in combination with bendamustine against DLBCL models both in vitro and in vivo. We also investigated the life-prolonging effect of YM155 in combination with bendamustine and rituximab in a disseminated DLBCL xenograft model. 
Materials and Methods

Cell culture
The human DLBCL cell line DB was purchased from the American Type Culture Collection (Manassas, VA, USA). The human DLBCL cell lines; WSU-DLCL2 and SU-DHL-8 were purchased from the German Resource Center for Biological Material (DSMZ, Braunschweig, Germany). Cells were cultured at 37 °C in a 5% CO 2 atmosphere in RPMI 1640 medium supplemented with 10% heat-inactivated fetal bovine serum (Sigma-Aldrich, St. Louis, MO, USA). All cell lines were authenticated by Short Tandem Repeat profiling (Promega, Madison, WI, USA).
Reagents and antibodies
Sepantronium bromide (YM155) was synthesized at Astellas Pharma Inc. (Tokyo, Japan), dissolved in dimethyl sulfoxide (DMSO), and diluted with culture medium. Rituximab and bendamustine were purchased from Genentech Inc. (San Francisco, CA, USA) and Sigma-Aldrich, respectively, and dissolved in phosphate buffered saline (PBS). For in vivo studies, bendamustine hydrochloride (Levact ® ), hereafter referred to as "bendamustine", was purchased from Mundipharma (Limburg, Germany). The doses of YM155 and bendamustine were expressed in terms of free base of each drug substance. All drugs were dissolved and diluted in saline just before administration. Anti-survivin antibody was purchased from R&D Systems Inc. (Minneapolis, MN, USA); phosho-ATM (S1981), phosho-p53 (S15), phosho-chk2 (T68), phospho-histone H2AX (S139), and phosho-cdc2 (Y15) from Cell Signaling Technology Inc. (Danvers, MA, USA); and β-actin from Sigma-Aldrich.
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Author Manuscript Published OnlineFirst on January 31, 2014; DOI: 10.1158/1078-0432.CCR-13-2707 9 data collection, 5000 events were acquired per sample and analyzed using CytoSoft software (Guava Technologies). Mean values were obtained from three independent assays. Bendamustine at 50 mg/kg was administered intravenously (i.v.) once on d 0. Body weight and tumor diameter were measured twice a week, and tumor volume was determined (length × width 2 × 0.5).
Subcutaneous xenograft model
Complete regression (CR) was defined as tumor regression to below the limit of palpation. The percent inhibition of tumor growth on d 21 was calculated for each group using the following formula: were administered as double combination (YM155 plus rituximab) or triple combination (YM155 plus rituximab plus bendamustine), and the condition of animals was monitored daily. Mice were scored as dead if any of the following signs of suffering were observed: cachexia, weakening, and difficulty moving or eating. Mice scored as dead were euthanized while under diethyl ether anesthesia. 18 F-FLT was synthesized in-house from its precursors as described previously (24) . The specific activity of 18 F-FLT exceeded 45.1 MBq/nmol (1.22 Ci/μmol) at the end of synthesis. For imaging studies, we used 5 mice per group for each independent experiment. Treatment regimens were the same as described above. 18 subsequently maintained in cages for 1 h to allow for 18 F-FLT uptake into tumors. Mice were anesthetized with 2.0%-2.5% isoflurane/O 2 gas and placed in a mouse imaging chamber (m2m Imaging Corp, Cleveland, OH, USA). A 5-min emission scan was performed using the PET scanner followed by CT imaging (500 μA, 80 kV). Regions of interest (ROI) were drawn around the boundaries of tumors in lymph nodes on coronal slices, and the observed maximum pixel value was normalized to the injected dose and body weight to give the maximum standardized uptake value (SUV max ).
F-3'-fluoro-3' deoxythymidine positron emission tomography ( F-FLT-PET) imaging
Analysis for synergy
The Bliss additivism model (28, 29) 
Statistical analysis
Values were expressed as mean ± standard error of the mean (SEM). Tumor volume and body weight on d 21 were compared between each single compound group and the combination group by using Student's t-test with SAS software (SAS Institute, Cary, NC, USA). For PET study, Quantitative ROI analysis was conducted by applying Student's t-test with GraphPad Prism (GraphPad Software, San Diego, CA, USA). For survival analysis, Kaplan-Meier curves were generated, and differences were assessed using log-rank test with GraphPad Prism. P-values less than 0.05 were considered significant. 
Results
Effect of YM155 in combination with bendamustine in DLBCL cell lines in vitro
We first evaluated the in vitro combined effect of YM155 with bendamustine in DLBCL cell lines. YM155 at 10 nmol/L combined with bendamustine (250 μmol/L for DB cells, 100 μmol/L for SU-DHL-8 cells, and 150 μmol/L for WSU-DLCL2 cells) were treated for 24 h or 48 h and assessed for cell viability and apoptosis induction, respectively. The combination of YM155 with bendamustine induced a greater decrease in cell viability than either agent alone. The percentages of cell growth inhibition, induced by YM155, bendamustine, combination of both agents, and bliss index were 14%, 54%, 86%, and 61% in DB cells; 39%, 39%, 82%, and 70% in SU-DHL-8 cells; and 46%, 54%, 93% and 86% in WSU-DLCL2 cells, respectively ( Figure 1A) . The combination induced a greater sub-G1 population, indicative of apoptosis, than either agent alone. The percentages of sub-G1 population induced by YM155, bendamustine, and combination of both were 5.9%, 6.5%, and 27% in DB cells; 19%, 32%, and 58% in SU-DHL-8 cells; and 46%, 30%, and 71% in WSU-DLCL2 cells, respectively ( Figure 1B ). observed in the combination treatment group as compared to each single treatment group ( Figure 2B ).
Antitumor effects of YM155 combined with bendamustine in a DB xenograft model
Mechanisms of action for combination of YM155 with bendamustine
Bendamustine is reported to induce DNA damage, which activated the Ataxia Telangiectasia Mutated Protein (ATM) pathway and G2/M arrest in multiple myeloma cells (30) . To investigate the mechanisms of action for the combination of YM155 with bendamustine, we examined the status of the ATM pathway regions, being >4. No bone marrow infiltration was detected ( Figure S2A ). In the triple combination group, PET signals in lymph nodes were decreased. Quantitative ROI analysis indicated that, in submandibular and inguinal lymph nodes of animals in the triple treatment group, the signals were significantly smaller than those found in the non-treatment group ( Figure 2SB ). The administration of YM155 alone, bendamustine combined with rituximab, or YM155 combined with rituximab extended the median survival from 45.5 to 68, 57.5, and 78 days, respectively. Further, the triple treatment combination: YM155/bendamustine/rituximab, significantly prolonged survival as compared with respective YM155 alone, bendamustine combined with rituximab, or YM155 combined with rituximab treatments (Figure 4 ). The median survival in the triple combination treatment group was 86 days.
Discussion
Here, we examined the therapeutic potential of YM155 in combination with bendamustine or bendamustine/rituximab against DLBCL both in vitro and in vivo. The intrinsic survivin in tested DLBCL cell lines is highly expressed ( Figure S1 ). We found that the combination of YM155 with bendamustine decreased cell viability to a greater extent than either single agent alone. Bliss additivism analysis revealed that the combined effect was synergistic ( Figure 1A) . The combination of YM155 with bendamustine induced greater apoptosis in DLBCL cell lines than either single agent alone ( Figure 1B) .
Similar results were obtained in multiple drug concentrations (data not shown). Further, this combination induced greater antitumor activity, including complete regression, than either single agent in a DB DLBCL xenograft model without affecting body weight ( Figure 2 ). Together, the results suggest that YM155 combined with bendamustine is effective for treating of DLBCL.
Bendamustine is reported to have multiple modes of action. Primarily, bendamustine has been shown to form DNA cross-links, that induces DNA damage and results in activating the ATM pathway (8, 30) . The ATM pathway is a central pathway to repair of DNA double strand break (DNA-DSBs) in DNA, thereby influencing genome stability and cell survival. ATM is a major regulator of the DNA damage response by activation of chk2, and p53 and leads to induction of response genes involved in cell cycle arrest, DNA repair, and/or apoptosis (31) . Secondarily, bendamustine also inhibits mitotic checkpoints and induces G2/M arrest (8, 30) . The expression of survivin is regulated in a cell cycle-dependent manner and peaks at mitosis (32). We showed that bendamustine induced DNA damage, bendamustine inhibited the bendamustine-induced activation of the ATM pathway and increased survivin expression, consequently promoting DNA damage and apoptosis than either single agent alone ( Figure 3A) . Survivin is known to be radiation resistance factor in tumor cells (33) . The expression of survivin was increased by ionizing radiation through chk2 activation in breast and colon cancer cells (34) . Further, survivin is reported to be linked to DNA-DSB repair by interaction with members of the DNA-DSB repair machinery (35) . Survivin siRNA impaired irradiation-induced DNA-DSB repair, as demonstrated by an increase of γ-H2AX, and resulted in increased apoptosis (35, 36) . YM155 is known to sensitize NSCLC cells to radiation and platinum agents both in vitro and in vivo, through the inhibition of DNA damage repair (37, 38) . As well, we demonstrated that survivin suppression by YM155 enhances the antitumor activity of docetaxel through the inhibition of survivin accumulation at G2/M in NSCLC (39) and melanoma cells (40) . Taken together, these results suggest that survivin suppression by YM155 enhances the antitumor activity of bendamustine through the inhibition of DNA damage repair responses as well as survivin-mediated cytoprotection at the G2/M phase.
In our previous studies, the combination of YM155 with rituximab exhibited a synergistic effect against B-cell NHL, including DLBCL (24), and STAT3 inhibition by rituximab contributed to the synergistic effect seen in WSU-DLCL2 and SU-DHL-4 DLBCL cell lines (41) , which suggested the possibility that YM155 would enhance the antitumor effect of bendamustine when combined with rituximab through different mechanisms in DLBCL. In the present study, we examined the life-prolonging effect of YM155 in combination with bendamustine and rituximab in a SU-DHL-8 disseminated xenograft model. DLBCL commonly develops clinically as disseminated disease (42) , and in this model, dissemination of tumors in lymph nodes was detected using 18 F-FLT-PET ( Figure 2SA ).
Author Manuscript Published OnlineFirst on January 31, 2014; DOI: 10.1158/1078-0432.CCR-13-2707 Activated B-cell-like DLBCL has been reported to be more resistant to CHOP or R-CHOP than germinal center B-cell-like DLBCL (GCB-DLBCL) (43, 44) . In preliminary studies, we confirmed that R-CHOP did not show antitumor activity against SU-DHL-8, an ABC-DLBCL xenografts (45) but did show antitumor activity against DB, GCB-DLBCL xenografts (data not shown). These facts indicate that this model recapitulates many features found in refractory DLBCL patients. In this model, the triple combination treatment resulted in decreased FLT-PET signals in lymph nodes ( Figure 2S ) and in significantly longer overall survival than either YM155 alone, or the combination of bendamustine with rituximab, or the combination of YM155 with rituximab ( Figure 4 ). In addition, the concentration of YM155 used here (1 mg/kg/day) can be clinical achieved concentration (21, 46) . The results suggest that the triple combination of YM155 with bendamustine and rituximab is expected to exert greater clinical benefits in patients with relapsed/refractory DLBCL than the sole combination of these two agents. In clinical settings, the combination of bendamustine with rituximab is a promising salvage regimen for patients with relapsed/refractory DLBCL after rituximab-containing chemotherapy. Despite its clinical benefits, the high dose bendamustine treatment was often limited due to development of hematologic toxicity, primarily lymphopenia, neutropenia, leukopenia, and thrombocytopenia (12) . YM155 monotherapy demonstrated modest anticancer activity with no serious hematologic events in patients with refractory DLBCL (26) . These data suggest that the combination of YM155 with bendamsutine and rituximab may be beneficial. However, further clinical investigation will be required to verify the tolerability and therapeutic potential of this triple combination regimen against relapsed/refractory
DLBCL.
Author Manuscript Published OnlineFirst on January 31, 2014; DOI: 10.1158/1078-0432. CCR-13-2707 In conclusion, here we have shown that YM155 enhances the antitumor activity of bendamustine against DLBCL models through inhibition of DNA damage responses as well as survivin-mediated cytoprotection at the G2/M phase. Further, the triple combination of YM155 with bendamustine and rituximab showed superior survival benefit as compared to double treatments. These data prompt further clinical investigations of YM155 in combination with bendamustine and rituximab for the treatment of 
